Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2017-01-31 Report Publication Anno…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Release Date of 2016 Full Year Preliminary Financial Results 1
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Cyclopharm Limited stating that the company will release its full year preliminary financial results for 2016 on a future date (6 February 2017). It does not contain any actual financial data or detailed results, but merely informs the market about the upcoming release. The document length is only 2693 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is a report publication announcement rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2017-01-31 English
Change of Director's Interest Notice 3 pages 109.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, nature of the interest, and dates. This is a formal notification of a director's personal share transactions, which aligns with the definition of Director's Dealing filings. The document is not a financial report, earnings release, or management information, but a regulatory disclosure of insider trading activity by a director.
2016-11-24 English
CYC Achieves USFDA Agreement For Technegas Trial Design 2 pages 129.6KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Cyclopharm Limited dated 23 November 2016, addressed to the Australian Securities Exchange. It announces that the company has received Special Protocol Assessment (SPA) agreement from the US FDA for a clinical trial design related to its Technegas product. The content focuses on regulatory approval progress and clinical trial plans rather than financial results, management changes, or shareholder voting. It is a regulatory announcement about a clinical trial protocol agreement with a regulatory body (US FDA). The document is not a financial report, earnings release, management discussion, or any other report type defined in the filing categories. It is a regulatory announcement about a significant development in the company's regulatory process. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-11-22 English
Change of Company Address 1 page 127.3KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Cyclopharm Limited to the Australian Securities Exchange (ASX) regarding a change of the company's registered office address. It references ASX Listing Rule 3.14, which pertains to notifying the exchange of changes in company details. The content is administrative and does not contain financial data, management changes, or other report types. The document length is 2865 characters, which is short and fits the profile of a regulatory announcement rather than a full report or detailed filing. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-10-30 English
Cyclopharm CEO Microcap Investment Conference Presentation 28 pages 823.8KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Cyclopharm Limited at the Australian Microcap Investment Conference dated 19 October 2016. It includes company overview, technology overview, financial highlights, product overview, growth opportunities, strategy, half-year and full-year financial results, balance sheet data, market expansion plans, and clinical trial updates. The content is structured as a slide presentation with charts, tables, and bullet points focusing on financial performance, strategic priorities, and market positioning. There is no indication that this is an official annual report (10-K), interim report (IR), or earnings release (ER) in the traditional regulatory filing sense. Instead, it is a comprehensive investor presentation aimed at providing detailed financial and strategic information to investors. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2016-10-18 English
Cyclopharm Business Update on Significant Milestones 3 pages 148.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Cyclopharm Limited dated 13 October 2016, providing updates on the successful completion of the first stage of USFDA clinical trials for Technegas, progress on sales strategies, an invitation from the IAEA for a new technology, and relocation plans. It discusses clinical trial phases, regulatory submissions, and strategic developments rather than presenting full financial statements or detailed financial performance data. The document is a corporate update aimed at shareholders and the market about operational and clinical progress, not a formal financial report or earnings release. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory certification or officer attestation. The content fits best as a Capital/Financing Update (CAP) because it relates to clinical trial progress, regulatory milestones, and strategic business developments that impact the company's capital and growth prospects. Therefore, the appropriate classification is CAP with high confidence.
2016-10-12 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.